Tagged Articles

long-term risks 18 articles

Long-term pancreatic cancer risks with class of type 2 diabetes drugs still unknown

Drugs in a class of Type 2 diabetes medications known as DPP-4 inhibitors may not increase the short-term risk of pancreatic cancer, but the long-term risks are still unknown, according to a new study published in the journal Diabetes, Obesity and Metabolism. The study was conducted by researchers with the University of North Carolina (UNC) Gillings School of Global Public Health and the UNC School of medicine, and focused on pancreatic cancer risks with DPP-4 inhibitors such as Januvia and Janumet (sitagliptin), and Tradjenta (linagliptin). DPP-4 inhibitors were first marketed in the United States in 2006 and have since become ... Read More

MBL granted A-Rod therapeutic use exemption for testosterone therapy

Yankees third baseman Alex Rodriguez, best known as A-Rod, was using a testosterone treatment during the 2007 season under a therapeutic use exemption from Major League Baseball, according to a new book titled Blood Sport: Alex Rodriguez, Biogenesis and the Quest to End Baseball’s Steroid Era. Testosterone supplements are a prescription medication approved by the Food and Drug Administration (FDA) to boost testosterone levels in men who have low levels of the hormone in their blood, a condition known as hypogondalism. The condition can result in symptoms such as low libido, weight gain, and fatigue. In recent years, aggressive marketing ... Read More

European Union approves new combination treatment for type 2 diabetes

European Union drug regulators have approved a new combination pill to treat type 2 diabetes. Vokanamet combines the new diabetes drug Invokana with the standard treatment metformin. The new treatment is made by Johnson & Johnson and will be marketed in Europe by Janssen-Cliag International. The active ingredient in Invokana is canagliflozin, which is in a class of diabetes medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs are designed to help reduce blood sugar levels by preventing the reabsorption of glucose from the kidneys back into the blood, and allows glucose to be excreted in the urine. The U.S. ... Read More

Alabama residents with Type 2 diabetes sought for long-term study on medication effectiveness

Researchers at the University of Alabama at Birmingham (UAB) are enrolling participants in an ongoing study on the long-term benefits and side effects with certain combinations of drugs to treat type 2 diabetes. Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness, or GRADE, is a national study that is being conducted at UAB and 36 other sites across the country. Enrollment began in June 2013, but more participants are being sought. More than 5,000 people will be enrolled in the study. Subjects must have type 2 diabetes that was diagnosed within the past five years and should not be on ... Read More

Participants sought to test long-term effects of popular type 2 diabetes drugs

Researchers at Washington University School of Medicine in St. Louis are seeking volunteers to participate in a study comparing the long-term risks and benefits of four widely prescribed diabetes drugs. The medications will be given in combination with the widely used metformin. The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study will span five years, during which time researchers will evaluate how the drugs affect blood sugar levels, diabetes complications and quality of life. Each drug’s side effects will also be noted. The research team also aims to examine individual factors associated with better or worse response to ... Read More

FDA delays decision on diabetes inhaler to review possible cancer risks

The Food and Drug Administration (FDA) has delayed its decision about whether to approve Mannkind Corp.’s Afrezza, an inhaled insulin treatment for diabetes, due to concerns about an increased risk of lung cancer. The delay comes just one week after an advisory panel recommended the approval of the therapy for both type 1 and type 2 diabetes under the condition that the drug company collect long-term data on cancer risks and other potential side effects. Afrezza is a whistle-sized device designed to deliver a fast-acting dose of insulin. It offers a convenient alternative for many diabetic patients who currently have to ... Read More

Japan approves new type 2 diabetes drug dapagliflozin

Japanese drug authorities have approved Forxiga (dapagliflozin) for the treatment of type 2 diabetes. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is a once-daily oral treatment that works independent of insulin to help remove excess glucose from the body. It is currently approved in more than 40 countries around the world, including the United States, where it is marketed under the brand name Farxiga. SGLT-2 inhibitors are a relatively new class of diabetes medications. It was the first of its kind to be approved in Europe, and the second, behind Johnson & Johnson’s Invokana, in the United States. The class ... Read More

Does testosterone therapy pose heart risks for women?

You probably wouldn’t know it from the male-targeted advertisements pushing hormone supplements to boost “Low T,” but testosterone therapy can provide similar benefits for women. The question is, does it also carry the same risk of heart attacks, strokes and death in women as it does for men? Testosterone is considered the male hormone, responsible for the maturation of the testis and prostate as well as the development of sexual characteristics such as increased muscle, bone mass and body hair. In general, adult men have about 7-8 times more testosterone pumping through their bodies than adult females. Estrogen, considered the ... Read More

More men getting testosterone treatment but may not need it

Many older American men start testosterone therapy without a real medical need, according to a study published in the Journal of Clinical Endocrinology & Metabolism. Levels of the male hormone testosterone typically drop as men age, causing symptoms such as low sex drive, weight gain and a lack of energy. Many drug companies now offer testosterone replacement products, such as AndroGel, Testim, and Axiron. These drugs require a doctor’s prescription after blood tests confirm that testosterone levels are below average. Many men in the United States have been lured by drug companies’ marketing campaigns that tout the benefits of testosterone ... Read More

Testosterone treatment linked to increased risk of heart attacks, strokes, death

Aggressive marketing campaigns by drug companies peddling testosterone treatments has resulted in an increasing number of men asking their doctors if they are a candidate for testosterone therapy. Low levels of testosterone, or “Low T” as the drug companies have dubbed it, can be blamed for a variety of symptoms from fatigue and low libido to muscle weakness and weight gain. But testosterone supplementation may not be the wonder therapy marketers are claiming it to be. Recent studies show that men who take the drugs are 30 percent more likely to have a heart attack, stroke, or die during a ... Read More